Jesse Lewin, MD
MOHS-Micrographic Surgery · New York, NYNPI 1285951251
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,400 of the $2,788 with a category attached, or 86.1%. Almirall LLC accounts for 87.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $2,540 and has fallen 97.1% since, to $75 in 2025.
Across 17 payments — averaging $164.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Almirall LLC$2K
- Regeneron Healthcare Solutions, Inc.$91
- Pfizer$72
- Johnson & Johnson$55
- Sun Pharmaceutical Industries Inc.$39
- Boehringer Ingelheim$22
- plus $70 from 4 others
What the payments were for
- Speaking & faculty fees$2,40086%
- Food & beverage$38814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Almirall LLC | 2 | $2,439 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| Pfizer | 3 | $72 |
| Johnson & Johnson | 2 | $55 |
| Sun Pharmaceutical Industries Inc. | 1 | $39 |
| Boehringer Ingelheim | 1 | $22 |
| AbbVie | 1 | $19 |
| Dermavant Sciences, Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Klisyri$2,400
How this compares
$2,788 in reported general payments places this provider in the 65th percentile of 75 mohs-micrographic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 70 | $251 |
| Doxycycline Hyclate | 28 | $237 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $154 |
| Amoxicillin | 25 | $62 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in New York
- Ellen MarmurNew York$186K
- Michael TassavorNew York$55K
- Jane YooNew York$42K
- Hamza BhattiNew York$40K
- Desiree RatnerNew York$32K
- Omar Torres LozadaNew York$13K
- Ronald SheltonNew York$10K
- Sarah YagermanNew York$8K
- John CarucciNew York$6K
- Faramarz SamieNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.